Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: Effects on radiation therapy

International Journal of Radiation Oncology Biology Physics

Volumn 42, Issue 4, 1998, Pages 899-903

  Li, Lingyun ^a   Rojiani, Amyn ^b   Siemann, Dietmar W ^a,c  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Combretastatin; KHT sarcoma; Vascular targeting

Indexed keywords

COMBRETASTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CANCER RADIOTHERAPY; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; FEMALE; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; SARCOMA; TUMOR BLOOD FLOW;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOOD VESSELS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; MICE; MICE, INBRED C3H; NECROSIS; SARCOMA, EXPERIMENTAL; STILBENES;

EID: 0031742231     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00320-4     Document Type: Conference Paper

References (20)

1. Folkman J., Shing Y. Angiogenesis. J Biol Chem. 267:1992;10931-10934.
2. Winlaw D.S. Angiogenesis in the pathobiology and treatment of vascular and malignant diseases. Ann Thorac Surg. 64:1997;1204-1211.
3. Hobson B., Denekamp J. Endothelial proliferation in tumors and normal tissue Continuous labeling studies . Br J Cancer. 49:1984;405-413.
4. Gastl G., Hermann T., Steurer M., Zmija J., Gunsilius E., Unger C., Kraft A. Angiogenesis as a target for tumor treatment. Oncology. 54:1997;177-184.
5. Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 333:1995;1757-1763.
6. Denekamp J. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol. 66:1993;181-196.
7. Dark G.G., Hill S.A., Prise V.E., Tozer G.M., Pettit G.R., Chaplin D.J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 57:1997;1829-1834.
8. Mahadevanv M.S., Meager A., Fiers W., Lewis G.P., Hart I.R. Role of tumor necrosis factor in flavone acetic acid induced vascular shutdown. Cancer Res. 50:1990;5537-5542.
9. Hill S.A., Sampson L.E., Chaplin D.J. Anti-vascular approaches to solid tumor therapy Evaluation of vinblastine and flavone acetic acid . Int J Cancer. 63:1995;119-123.
10. Pettit G.R., Cregg G.M., Singh S.B. Antineoplastic agents, 122. Constituents of Combretum caffrum. J Nat Prod. 50:1987;386-391.
11. Pettit G.R., Singh S.B., Hamel E., Lin C.M., Alberts D.S., Garcia-Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia. 45:1989;209-211.
12. Sackett D.L. Podophyllotoxin, steganacin and combretastatin Natural products that bind at the colchicine site of tubulin . Pharmacol Ther. 59:1993;163-228.
13. el-Zayat A.A., Degen D., Drabek S., Clark G.M., Pettit G.R., Von Hoff D.D. In vitro evaluation of the antineoplastic activity of combretastatin A-4, a natural product from Combretum caffrum (arid shrub). Anticancer Drugs. 4:1993;19-25.
14. Thomson J.E., Rauth A.M. An in vitro assay to measure the viability of KHT tumor cells not previously exposed to culture conditions. Radiat Res. 58:1974;262-276.
15. Allalunis-Turner M.J., Siemann D.W. Recovery of cell subpopulations from human tumor xenografts following dissociation with different enzymes. Br J Cancer. 54:1986;615-622.
16. Siemann D.W. Chemosensitization of CCNU in KHT murine tumor cells in vivo and in vitro by the agent RB 6145 and its isomer PD 144872. Radiother Oncol. 34:1995;47-53.
17. Baguley B.C., Holdaway K.H., Thomsen L.L., Zhuang L., Zwi L.J. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine Evidence for a vascular mechanism . Eur J Cancer. 27:1991;482-487.
18. Chaplin D.J., Pettit G.R., Parkins C.S., Hill S.A. Antivascular approaches to solid tumor therapy Evaluation of tubulin binding agents . Br J Cancer. 74:1996;S86-S88.
19. O'Brien C. Combretastatin A-4 targets vascular damage to tumors. Mol Med Today. 3:1997;369.
20. Siemann DW, Johansen IM, Horsman MR. Radiobiological hypoxia in the KHT sarcoma: Predictions using the eppendorf histograph. Int J Radiat Oncol Biol Phys. 1998;40:1171-1176.